This page tracks all clinical trials for Progressive Supranuclear Palsy (PSP), a primary 4R-tauopathy. PSP has historically been challenging to treat due to limited understanding of disease mechanisms and difficulties in patient recruitment due to disease rarity. The therapeutic pipeline remains small compared to Alzheimer's Disease or Parkinson's Disease, but several approaches are being explored.
Current Trial Landscape
| Status | Count | Notes | |--------|-------|-------| | Recruiting | 1 | First-in-human tau ligand | | Active, Not Recruiting | 2 | Imaging biomarkers, palliative care | | Completed | 6+ | Includes failed and successful | | Terminated/Withdrawn | Multiple | Important for understanding |
Active Trials
Recruiting
NCT07348276 — First-in-Human Study for Safety and Evaluation of Two 4R Tau Ligands in PSP
Status: Recruiting
Phase: Early Phase 1
Sponsor: Invicro
Intervention: Two novel 4R tau PET ligands
Purpose: First-in-human evaluation of tau tracer specificity for PSP
Significance: Improved tau imaging could enable better diagnosis and trial enrollment
Active, Not Recruiting
NCT05222386 — Community Outreach for Palliative Engagement — PSP
Status: Active, not recruiting
Sponsor: University of Rochester
Purpose: Palliative care approaches for PSP patients
Significance: Addresses quality of life and symptomatic management
...
Clinical Trials in Progressive Supranuclear Palsy
Overview
This page tracks all clinical trials for Progressive Supranuclear Palsy (PSP), a primary 4R-tauopathy. PSP has historically been challenging to treat due to limited understanding of disease mechanisms and difficulties in patient recruitment due to disease rarity. The therapeutic pipeline remains small compared to Alzheimer's Disease or Parkinson's Disease, but several approaches are being explored.
Current Trial Landscape
| Status | Count | Notes | |--------|-------|-------| | Recruiting | 1 | First-in-human tau ligand | | Active, Not Recruiting | 2 | Imaging biomarkers, palliative care | | Completed | 6+ | Includes failed and successful | | Terminated/Withdrawn | Multiple | Important for understanding |
Active Trials
Recruiting
NCT07348276 — First-in-Human Study for Safety and Evaluation of Two 4R Tau Ligands in PSP
Status: Recruiting
Phase: Early Phase 1
Sponsor: Invicro
Intervention: Two novel 4R tau PET ligands
Purpose: First-in-human evaluation of tau tracer specificity for PSP
Significance: Improved tau imaging could enable better diagnosis and trial enrollment
Active, Not Recruiting
NCT05222386 — Community Outreach for Palliative Engagement — PSP
Status: Active, not recruiting
Sponsor: University of Rochester
Purpose: Palliative care approaches for PSP patients
Significance: Addresses quality of life and symptomatic management
NCT07105384 — Quantification Tools for a Novel Tau PET Marker in PSP
Status: Active, not recruiting
Phase: Phase 2
Sponsor: Fundacion Clinic per a la Recerca Biomédica
Failed trials provide essential evidence about disease mechanisms and therapeutic approaches. Documenting WHY they failed is crucial for future development.